Keros Therapeutics, Inc. (KROS) · Nov 5, 2026 · Earnings
Beat — Diluted EPS $0.70 vs approximately $0.96 loss consensus; revenue $40.0M vs approximately $14.76M
Keros earnings beat consensus on $40 million of Takeda-related license revenue, while its wholly owned pipeline remains early-stage.
Keros is a cash-rich, clinical-stage biotech rebuilding around wholly owned programs after licensing elritercept to Takeda; its main current development push is rinvatercept in Duchenne muscular dystrophy, with the Phase 2 trial already underway. Published estimates expected a loss and roughly $14.8 million of quarterly revenue, so the reported $0.70 diluted EPS and $40.0 million of revenue were a clear headline beat.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Total revenue (Income Statement) | $40.0M | $14.3M | ~$14.76M |
| Diluted EPS (Income Statement) | $0.70 | $(0.18) | ~$(0.96) |
| R&D expense (Income Statement) | $20.5M | $19.5M | |
| Cash and equivalents (Balance Sheet) | $259.5M | $287.4M at Dec. 31, 2025 |
The beat is mostly a licensing-accounting event, not operating acceleration. The quarter included $40 million of license revenue tied to the Takeda agreement, which had already produced a disclosed additional milestone announcement in September; the filing itself says the improvement in net income was primarily due to revenue related to that agreement. That makes the earnings surprise real but lower quality: R&D spending still rose to $20.5 million as Keros funds its own pipeline, while there is no product revenue or new clinical efficacy readout.
The underlying business story is broadly unchanged, with runway intact. Keros remains dependent on clinical execution rather than commercial sales, but its balance sheet is not the immediate constraint: cash declined from $287.4 million at year-end to $259.5 million at September 30, and management says that balance funds operations into the second half of 2028. 〔0〕
The next meaningful value test is clinical, not financial. The first DMD patient was dosed in September, and initial data are expected in the first half of 2027. 〔1〕 Until then, the Takeda milestone improves reported earnings and extends visibility, but does not materially validate rinvatercept or KER-206.
Bottom line: Keros beat estimates, but mainly because of a largely anticipated Takeda milestone. The quarter supports financial durability more than it changes the early-stage pipeline story.
Initial DMD Phase 2 data, first half 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!